Winning the 2008 NSW BioFirst Commercialisation award has come at exactly the right time for Special Phage Holdings, which has treated a patient in the clinic and is currently looking at a second round of private fundraising to develop its portfolio of bacteriophages

Arana humanises VEGF-D antibody

Xceed and Metabolic trade PolyNovo Biomaterials

Alchemia registers loss, expects to be in profit in 2010

NuSep to purchase NxGen for $25 million

The antisense concept has been around for 30 years and now therapies are on the market and in the clinic, including a recently reported Phase IIa trial by Melbourne company Antisense Therapeutics.

Unlisted Queensland biotech Xenome has reported good results in a Phase II trial of its candidate for chronic cancer pain relief and raised a good amount of cash to further its clinical development.

Arana files IND application for rheumatoid arthritis candidate

Astronomer named as new chief scientist

Neuren, Norwood Abbey, NuSep, Anadis, Incitive, Ambri

Western Australian company Orthocell is pioneering biological therapies to repair and regenerate damaged tendons and ligaments.

Graham Macdonald named as ASCC interim board chair

Molloy joins Viralytics

Sydney’s Centenary Institute purchased a new multiphoton microscope last year and used it to lure one of the world’s leading experts in intravital two-photon microscopy to Australia.

A team from UTS is applying technology more traditionally used in forensic science to look at disease, imaging the trace metals in tissue samples in a new technique called elemental bioimaging.